Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus Inc. (Nasdaq: BVS), a global leader in active healing innovations, has announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference. Mark Singleton, the company's senior vice president and chief financial officer, will engage in a fireside chat on Wednesday, August 14, 2024, at 9:00 a.m. ET.
The event will feature a live webcast of the presentation, followed by a question-and-answer session. Interested parties can access the webcast through the 'Investors' section of Bioventus' website at www.bioventus.com. The presentation will also be available for replay on the site after the event concludes, providing an opportunity for those unable to attend live to catch up on the company's insights and updates.
Bioventus (Nasdaq: BVS) reported strong Q2 2024 financial results, with revenue increasing 10.3% to $151.2 million and organic growth of 13.9%. The company saw double-digit growth in Pain Treatments and Surgical Solutions. Despite a net loss of $32.1 million due to a non-cash impairment charge, Adjusted EBITDA grew 22.4% to $34.5 million. Gross margin expanded by 350 basis points, and cash from operations increased 40.5% to $15.2 million.
Based on strong performance, Bioventus raised its full-year 2024 guidance, now expecting net sales of $557-567 million, Adjusted EBITDA of $104-107 million, and Non-GAAP EPS of $0.36-0.42. The company is focusing on executing strategic priorities, including potential divestiture of its Advanced Rehabilitation Business to reduce debt and focus on core operations.
Bioventus Inc. (Nasdaq: BVS), a global leader in active healing innovations, has announced its plans to release second quarter fiscal year 2024 financial results on August 6, 2024, before the market opens. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update.
Interested parties can participate in the conference call by dialing 1-833-636-0497 and referring to the Bioventus Inc. Conference Call. Additionally, a live webcast of the call and accompanying materials will be available on the company's Investor Relations website. The webcast will be archived and accessible for replay until August 5, 2025.
Apyx Medical announced the retirement of Andrew Makrides as Chairman of the Board, who served the company since 1982, and the appointment of Stavros Vizirgianakis as the new Chairman. Makrides contributed to the company's growth over the years, while Vizirgianakis brings extensive medical device industry experience to the role.
Bioventus Inc. (Nasdaq: BVS) reported strong first-quarter financial results with a revenue increase of 8.7% and organic growth of 15.3%. The company raised its full-year 2024 financial guidance, reflecting enhanced revenue growth and strategic execution. Gross margin expanded significantly, and adjusted EBITDA from continuing operations increased by 33.5%. Bioventus achieved key milestones, including revenue growth in Pain Treatments and Surgical Solutions, liquidity enhancement, and EU MDR Certification for Exogen Bone Stimulation System. The company now expects net sales of $535 million to $550 million, adjusted EBITDA of $94 million to $99 million, and non-GAAP EPS of $0.25 to $0.33 for 2024.
Bioventus Inc. (Nasdaq: BVS) will release its financial results for the first quarter of fiscal year 2024 on May 7, 2024. The management will conduct a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update. Participants can join the call by dialing 1-833-636-0497 or accessing the live webcast on the company's website. The webcast will be available for replay until May 6, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.